This raises the possibility of considering therapeutic BACE2 inhibition for conditions with reduced VEGFR3 signaling, such as Milroy disease, which presents with lymphedema and can be caused by a heterozygous loss of VEGFR3 function (56). The gene discussed is FLT4; the disease is lymphedema.